Todas las investigaciones
Activo, no reclutandoFASE3INTERVENCIONISTA

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

This research study, called a Phase 3 trial, investigated a new medication called mitapivat. It was for adults (18 years and older) who have a genetic blood condition called thalassemia (either alpha or beta type) but don't need regular blood transfusions. The main goal was to find out if mitapivat was better than a placebo (a dummy pill) at improving anaemia, which is a common problem for people with thalassemia. Participants were divided into two groups: one received mitapivat, and the other received the placebo, to see how the new drug affected their red blood cells and overall health. The study also looked at how safe the new treatment was.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE3
Patrocinador
Agios Pharmaceuticals, Inc.
Objetivo de inscripción
194
Inicio
20 Dic 2021
Estimación de finalización
01 Dic 2028

Resultados

Resultados de este estudio

Publicado January 2025

Se han publicado los resultados de este estudio.

Resultado principal
Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline
Hb response is defined as ≥10 grams/ liter (g/L) (1.0 gram per deciliter) (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb response was tested using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Resultados completos en el registro

¿De qué trata este estudio?

Imagine your blood cells are like tiny delivery vans carrying oxygen around your body. If you have thalassemia, these vans aren't made quite right, so they can't carry enough oxygen. This often leads to feeling tired and weak, a condition known as anaemia. Some people with thalassemia need regular blood transfusions, but this study focused on those who generally don't – a group called 'non-transfusion-dependent' thalassemia.

The medication being tested in this study is called mitapivat. It's a new type of drug designed to help your red blood cells work better. The researchers wanted to see if taking mitapivat could improve the anaemia in people with thalassemia, meaning they might feel less tired and have healthier blood counts without needing transfusions or other treatments as often. They compared it to a 'dummy' pill (a placebo) to make sure any improvements were actually due to mitapivat.

This study is important because it could offer a new treatment option for people living with non-transfusion-dependent alpha- or beta-thalassemia. Finding ways to manage anaemia more effectively, without the need for frequent medical procedures, could significantly improve daily life for those with this condition. The study also carefully checked the safety of mitapivat to ensure that any potential benefits outweigh the risks.

Puntos clave

  • This study tested a new drug, mitapivat, for a type of thalassemia.
  • It focused on adults (18+) who don't need regular blood transfusions.
  • The main goal was to see if mitapivat improved anaemia compared to a dummy pill.
  • Participation involved taking the study drug and regular health checks.
  • It could offer a new way to manage thalassemia for some patients.
  • Patient safety was monitored closely throughout the trial.

¿Quién puede ser elegible?

This study was looking for adult volunteers, aged 18 or older, who have been diagnosed with a specific type of thalassemia (either alpha or beta) that doesn't usually require regular blood transfusions. To be considered, your haemoglobin levels (a measure of red blood cells) needed to be at a certain level or below.

You couldn't join if you were pregnant or breastfeeding, or if you had certain other serious health problems or had received particular treatments in the past, like stem cell transplants or gene therapy. Also, if you were taking certain medications for your blood condition, you might have had to stop them for a period before joining. Women who could get pregnant needed to agree to use effective contraception during and after the study.

Crucially, you couldn't have had a blood transfusion in the 8 weeks leading up to the study, nor during the screening period. If you were taking a medication called hydroxyurea, your dose needed to have been stable for at least 16 weeks.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have a diagnosis of alpha- or beta-thalassemia?
  3. Do you generally NOT need regular blood transfusions?
  4. Have you NOT had a blood transfusion in the last 8 weeks?
  5. ¿No estás embarazada ni amamantando?
  6. Are you able to attend regular clinic appointments?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you were eligible and chose to take part, you would have attended regular appointments at a clinic. You would have been given a study drug, either mitapivat or a placebo (a dummy pill), to take. Neither you nor your doctor would know which one you were receiving. You would have had blood tests taken regularly to monitor your red blood cell levels and to check for any side effects. You would also have given details about how you were feeling and any changes in your health. The study lasted for a significant period to properly assess the long-term effects and safety of the drug.

Riesgos y beneficios potenciales

Taking part in any clinical study has potential benefits and risks. The potential benefit of this study was that mitapivat might improve your anaemia and overall well-being, potentially reducing the need for other treatments. However, like all medications, mitapivat could also have side effects, which might have varied from mild to more serious. The study carefully monitored all participants for any adverse effects. You would have been given detailed information about these before deciding to join, and you would have had the right to withdraw from the study at any time without giving a reason, and this would not affect your future medical care.

Locations (68)

  • San Diego Hospital, UC San Diego Health
    Código postal verificado
    La Jolla, Estados Unidos
  • Stanford Medicine
    Código postal verificado
    Palo Alto, Estados Unidos
  • Hospital General de Massachusetts
    Código postal verificado
    Boston, Estados Unidos
  • Weill Cornell Medical Center
    Código postal verificado
    Nueva York, Estados Unidos
  • Duke University Medical Center
    Código postal verificado
    Durham, Estados Unidos
  • Penn Medicine - University of Pennsylvania Health System
    Código postal verificado
    Filadelfia, Estados Unidos
  • Universidade de Caxias do Sul
    Código postal verificado
    Caxias do Sul, Brazil
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
    Código postal verificado
    Ribeirão Preto, Brasil
  • HEMORIO Instituto Nacional de Hematologia
    Código postal verificado
    Rio de Janeiro, Brazil
  • Praxis Pesquisa Medica
    Código postal verificado
    Santo André, Brazil
  • GSH Banco de Sangue de São Paulo
    Código postal verificado
    São Paulo, Brasil
  • Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo
    Código postal verificado
    São Paulo, Brasil

Preguntas comunes

What is thalassemia?

Thalassemia is a blood disorder you're born with, where your body doesn't make enough healthy red blood cells, leading to tiredness and weakness (anaemia).

What does 'non-transfusion-dependent' mean?

It means you have thalassemia, but you don't typically need regular blood transfusions to manage your condition.

¿Qué es un 'placebo'?

A placebo is a dummy pill that looks just like the real drug but contains no active medicine. It helps researchers see if the real drug is truly effective.

Why were women of child-bearing potential asked to use contraception?

It's standard practice in drug studies to protect unborn babies, as the effects of new medications on pregnancy are often unknown.

Can I still join if I'm taking other medicines for thalassemia?

It depends on the medicine. If you're on hydroxyurea, your dose needed to be stable. If you were taking certain other blood-stimulating agents, you would have had to stop them some time before joining.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.